Dario Longo (21/12/1976) received the M.Sc. degree in Chemistry and Pharmaceutical Technologies in 2002 and was awarded his Ph.D. in Biochemistry Sciences at the University of Turin, Italy, in 2007. Since 2003 he worked as a research assistant at the Department of Chemistry developing computational approaches for improving Magnetic Resonance Imaging (MRI)-based contrast agents. In 2008 he moved to the Department of Molecular Biotechnology and Health Sciences at the University of Torino working on MRI-CEST contrast agents. In 2014 he became a Junior Group Leader at the Molecular Imaging Center of the University of Torino focusing on the development of imaging-based procedures (MRI/PET/OI/OA) at preclinical level. In 2018 he got a permanent position as First Researcher at the Institute of Biostructures and Bioimaging (IBB) of the Italian National Research Council (CNR) to establish his own group. From 2020 he has been appointed Head of the Research Unit of Torino of the IBB-CNR. His research activities deal with the development of new contrast agents (Gd chelates, CEST) and approaches focused on the in vivo characterization of tumor microenvironment (pH, metabolism and vascularization) and for the non-invasive assessment of treatment response.  He is coauthor of more than 60 publications and book chapters on peer reviewed international journals and of four patents in developing new contrast agents and procedures for in vivo pH measurements. In 2020 he has been nominated as Board Member of the European Society for Molecular Imaging (ESMI) and currently is a Contract Professor in Molecular Imaging at the University of Torino. He is project leader on a grant from AIRC (The Italian Association for Cancer Research) related to tumor pH imaging (AIRC MFAG 2017 #20153) and currently working on several EU-funded research projects involving MRI-based approaches in the area of cancer.